Диссертация (Токсические фосфорные некрозы лицевого черепа), страница 39
Описание файла
Файл "Диссертация" внутри архива находится в папке "Токсические фосфорные некрозы лицевого черепа". PDF-файл из архива "Токсические фосфорные некрозы лицевого черепа", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 39 страницы из PDF
Hess L.M., Jeter J.M., Benham-Hutchins M., Alberts D.S. Factors associated withosteonecrosis of the jaw among bisphosponate users // Am J Med. 2008 June ; 121(6):475–483.e3. doi:10.1016/j.amjmed.2008.01.047.197. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: newtherapeutic agents for the treatment of bone tumors.
Trends Mol Med 2004;10:337–343.[PubMed: 15242682])198. Hirbe A., Morgan E.A., Uluçkan O, Weilbaecher K. Skeletal complications of thebreast cancer therapies // Clin Cancer Res. 2006 October 15; 12(20 Pt 2): 6309s–6314s.199. Hjorting-Hansen E. Decortication in treatment of osteomyelitis of the mandible.ORAL SURG ORAL MED ORAL PATHOL 1970;29:641-55.200. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., NookaA., Sayegh G., Guarneri V., Desrouleaux K., Cui J., Adamus A., Gagel R.F.,Hortobagyi G.N. Frequency and Risk Factors Associated With Osteonecrosis of the Jawin Cancer Patients Treated With Intravenous Bisphosphonates // J Bone Miner Res2008;23:826–836.201.
Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patientsreceiving intravenous bisphosphonate therapy. J Clin Oncol. 2006 ASCO AnnualMeetingProceedings(postmeetingedition).2006;24:8528.Availableathttp://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528. Accessed on August 14,2006202. Hoppe W, Utz W, Wulfbekel E. Zur Pathogenese der Osteomyelitis siccamandibulae. Dtsch Zahnarztl Z 1969;24:1055-7.203.
Hughes DE, MacDonald BR, Russel RG, Gowen M: Inhibition of osteoclastlikemcell formation by bisphosphonates in longterm cultures of human bone marrow. JClin Invest 1989, 83: 1930-1935.204. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR,Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and invivo. J Bone Miner Res 1995, 10:1478-1487.318205. Hughes J. P. W., Baron R., Buckland D. H., Cooke M. A., Craig J. D., DuffieldD. P., Grosart A. W., Parkes P. W. J., Porter A. Phosphorous necrosis of the jaw: apresent day study with clinical and biochemical study // Brit. J.
industr. Med. - 1962. –19. – P 83-99206. Jacobsson S, Hallin 0, Hollender L, Hansson CG, Lindstrlim J. Fibro-osseouslesion of the mandible mimicking chronic osteomyelitis. ORAL SURG ORAL MEDORAL PATHOL 1975; 40:433-44.207. Jacobsson S, Heyden G. Chronic sclerosing osteomyelitis of the mandible:histologic and histochemical findings. ORAL SURG ORAL MED ORAL PATHOL1977;43:357-64.208.
Jacobsson S, Hollender L, Lindberg S, Larsson A. Chronic sclerosingosteomyelitis of the mandible. ORAL SURG ORAL MED ORAL PATHOL1978;45:167-74.209. Jacobsson S, Hollender L. Treatment and prognosis of diffuse sclerosingosteomyelitis (DSO) of the mandible. ORAL SURG ORAL MED ORAL PATHOL1980;49:7-14.210. Jacobsson S. , Hollender L, Lindberg S, Larsson A. Chronic sclerosingosteomyelitis of the mandible. Scintigraphic and radiographic findings.
Oral Surg OralMed Oral Pathol. 1978 Feb;45(2):167-74.211. Jacobsson S. Dahlen G. Mijller AJR. Bacteriologic and serologic investigation indiffuse sclerosing osteomyelitis: (DSO) of the mandible. ORAL SURG ORAL MEDORAL PATHOL 1982; 54:506-l 1.212. Jacobsson S. Diffuse sclerosing osteomyelitis of the mandible. Int J Oral Surg1984;13:363-85.213.
JACOBSSON, S. & HOLLENDER, L.; Treatment and prognosis of diffusesclerosing osteomyelitis (DSO) of the mandible. Oral Surg. 1980:49: 4-14.214. Johanssen A. Chronic sclerosing osteomyelitis of the mandible. Acta Radio1Diagn 1977;18:360-8.215. Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and twodiphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973, 11:269-280.319216. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy forosteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81(8):1100–3217.
Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP: Humancathepsin k cleaves native type I and II collagens at the N-terminal end of the triplehelix. Biochem J 1998, 331: 727-732.218. Kanis J.A.,O’Rourke N.,McCloskey E. Consequences of neoplasia inducedresorption and the use of clodronate (Review)// Int. J. Oncol.– 1994.
– Vol. 5. – P. 713–731.219. Kanis JA (1995). Bone and cancer: pathophysiology and treatment of metastases.Bone 17(Suppl):101S-105S.220. Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomizedrats. Physiol Res 1998;47:237-240.221.
Kawai T, Murakami S, Sakuda M, Fuchihata H. Radiographic investigation ofmandibular periostitis ossificans in 55 cases. Oral Surg Oral Med Oral Pathol OralRadiol Endod. 1996 Dec;82(6):704-12.222. Killey HC, Kay LW, Wright HC. Subperiosteal osteomyelitis of the mandible. Aclinical survey and experimental study. Oral Surg Oral Med Oral Pathol. 1970Apr;29(4):576-89.223. Kraj M, Ryszard P, Stanislaw M, Owczarska K 2006 The incidence of jawosteonecrosis in multiple myeloma patients treated with bisphosphonates.
Acta PolPharm 63:450–452.224. Kumar V., Pass B., Guttenberg S.A., Ludlow J., Emery R.W., Tyndall D.A.,Padilla R.J. Bisphosphonate-related osteonecrosis of the jaws // J Am Dent Assoc2007;138;602-609225. Kyle R.A., Yee G.C., Somerfield M.R., Flynn P.J., Halabi S., Jagannath S.,Orlowski R.Z., Roodman D.G., Twilde P., Anderson K. American Society of ClinicalOncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates inMultiple Myeloma // J Clin Oncol 25:2464-2472320226. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newlydiagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003227. Kyrgidis A., Vahtsevanos K., Koloutsos G., Andreadis C., Boukovinas I.,Teleioudis Z., Patrikidou A., Triaridis S.
Bisphosphonate-Related Osteonecrosis of theJaws: A Case-Control Study of Risk Factors in Breast Cancer Patients // JCO Oct 12008: 4634-4638.228. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR,Gollbach KL, Hayman SR, et al.Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.Mayo Clin Proc 2006;81:1047–53.229. Lam D.K., Sándor G.K.B., Holmes H.I., Evans A.W., Clokie C.M.L. A Reviewof Bisphosphonate-Associated Osteonecrosis of the Jaws and Its Management //www.cda-adc.ca/jcda/vol-73/issue-5/417.html230.
Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibitsthe growth of prostate cancer cells. Cancer Res 2001;61:2602-8.231. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK.Does avascular necrosis of the jaws in cancer patients only occur following treatmentwith bisphosphonates? J Craniomaxillofac Surg. 2005;33: 395-403.232. Levin L., Laviv A., Schwartz-Arad D. Denture-Related Osteonecrosis of theMaxilla Associated With Oral Bisphosphonate Treatment // J Am Dent Assoc2007;138;1218-1220233. Licata AA. Discovery, clinical development, and therapeutic uses ofbisphosphonates.
Ann Pharmacother 2005;39:668-77.234. Lichty G, Langlais RP, Aufdemorte T. Garré's osteomyelitis. Literature reviewand case report. Oral Surg Oral Med Oral Pathol. 1980 Oct;50(4):309-13.235. Logan W.M. Phosphoro - necrosis // J Natl Med Assoc. 1923 Jan–Mar; 15(1):67–69.236. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitisof the jaw in long-term survivors of multiple myeloma: a new clinical entity [Letter].Am J Med. 2004;117:440-1.321237. Lund T., Abildgaard N., Andersen T.L., Delaisse J-M, Plesner T.
Multiplemyeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specificalkaline phosphatase can be used in daily practice to detect imminent osteolysis //European Journal of Haematology 84 (412–420)238. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates[Letter]. N Engl J Med. 2005;353:99-102.239. Malmstriim M, Fyhrqvist F, Kosunen TU, Tasanen A. Immunological features ofpatients with chronic sclerosing osteomyelitis of the mandible. Int J Oral Surg1983;12:6-1240.
Marini JC. Do bisphosphonates make children’s bones better or brittle? N Engl JMed 2003;349:423-6.241. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonateassociated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc.2005;136:1669-74.242. Martin TJ, Grin V. Bisphosphonates – mechanisms of action. AustralianPrescriber 2000;23:130-132.243. Marunick M, Miller R, Gordon S. Adverse oral sequelae to bisphosphonateadministration. J Mich Dent Assoc. 2005;87:44-9.244. Marx RE, Carlson ER, Smith BR, Toraya N. Isolation of Actinomyces speciesand Eikenella corrodens from patients with chronic diffuse sclerosing osteomyelitis.
